Mizuho Issues Pessimistic Forecast for Inspire Medical Systems (NYSE:INSP) Stock Price

Key Points

• Mizuho cut its price target on Inspire from $70 to $55 while retaining an "outperform" rating, which implies only about a 0.43% upside from the stock's current price.
• Inspire beat Q1 EPS and revenue, but management issued a materially lower FY2026 guide (revenue $825M–$875M; EPS $0.75–$1.25), blaming reimbursement/coding headwinds and a WISeR disruption, triggering a negative market reaction and analyst downgrades.
• The sell-side consensus remains an average "Hold" (4 Buys, 15 Holds, 1 Sell) with a consensus price target of $94.89, while the stock trades near $54.77 and is roughly 94.9% institutionally owned.

Inspire Medical Systems (NYSE:INSP - Get Free Report) had its price objective cut by equities research analysts at Mizuho from $70.00 to $55.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has an "outperform" rating on the stock. Mizuho's target price would indicate a potential upside of 0.43% from the stock's current price.

Several other equities analysts have also issued reports on INSP. Evercore reissued an "outperform" rating on shares of Inspire Medical Systems in a research note on Friday, February 27th. Wolfe Research lowered Inspire Medical Systems from an "outperform" rating to a "peer perform" rating in a research note on Friday, February 13th. Stifel Nicolaus cut their price target on Inspire Medical Systems from $85.00 to $70.00 and set a "buy" rating on the stock in a report on Friday, April 10th. Wells Fargo & Company set a $70.00 price target on Inspire Medical Systems and gave the stock an "equal weight" rating in a report on Thursday, February 12th. Finally, Morgan Stanley set a $60.00 price target on Inspire Medical Systems in a report on Wednesday, February 18th. Four research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Inspire Medical Systems has an average rating of "Hold" and a consensus price target of $94.89.

Inspire Medical Systems Trading Down 3.4%

INSP opened at $54.77 on Tuesday. The stock's 50-day moving average price is $56.73 and its 200 day moving average price is $79.64. Inspire Medical Systems has a 12-month low of $48.30 and a 12-month high of $163.35. The firm has a market cap of $1.58 billion, a price-to-earnings ratio of 11.00, a PEG ratio of 2.92 and a beta of 0.83.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its earnings results on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.38. Inspire Medical Systems had a return on equity of 10.96% and a net margin of 15.95%.The firm had revenue of $204.58 million for the quarter, compared to analyst estimates of $200.04 million. During the same quarter in the prior year, the company earned $0.10 EPS. Inspire Medical Systems's revenue was up 1.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, research analysts forecast that Inspire Medical Systems will post 1.82 earnings per share for the current year.

Institutional Investors Weigh In On Inspire Medical Systems

Large investors have recently bought and sold shares of the stock. Principal Financial Group Inc. increased its holdings in shares of Inspire Medical Systems by 1.0% in the 1st quarter. Principal Financial Group Inc. now owns 126,788 shares of the company's stock valued at $6,540,000 after acquiring an additional 1,269 shares during the last quarter. Fifth Third Bancorp lifted its stake in Inspire Medical Systems by 1,794.4% during the first quarter. Fifth Third Bancorp now owns 6,441 shares of the company's stock worth $332,000 after purchasing an additional 6,101 shares during the last quarter. New York State Teachers Retirement System lifted its stake in Inspire Medical Systems by 9.3% during the first quarter. New York State Teachers Retirement System now owns 23,599 shares of the company's stock worth $1,217,000 after purchasing an additional 2,004 shares during the last quarter. Y Intercept Hong Kong Ltd lifted its stake in Inspire Medical Systems by 124.1% during the first quarter. Y Intercept Hong Kong Ltd now owns 158,274 shares of the company's stock worth $8,164,000 after purchasing an additional 87,639 shares during the last quarter. Finally, Leonteq Securities AG lifted its stake in Inspire Medical Systems by 187.3% during the first quarter. Leonteq Securities AG now owns 22,812 shares of the company's stock worth $1,177,000 after purchasing an additional 14,873 shares during the last quarter. Hedge funds and other institutional investors own 94.91% of the company's stock.

Trending Headlines about Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q1 beat on EPS and revenue: Inspire reported $0.10 EPS (vs. expectations for a loss) and $204.6M in revenue, a modest year-over-year increase and slightly above consensus — shows underlying procedure demand held up in the quarter. Read More.
• Neutral Sentiment: Earnings call and details: Management discussed operational drivers and the timing impact of reimbursement/coding headwinds and the WISeR disruption — useful for modeling cadence but contained no offsetting near-term revenue levers. Read More.
• Negative Sentiment: Guidance cut materially lowers FY26 targets: Inspire lowered FY2026 revenue guidance to $825M–$875M and EPS to $0.75–$1.25, well below consensus — the reset is the main driver of the trader reaction and forces downward revisions to FY26 models. Read More.
• Negative Sentiment: Reimbursement/coding and WISeR disruption cited as causes: Management specifically blamed coding changes and disruption related to WISeR (workflow/servicing) for reduced procedure volumes and reimbursement uncertainty — this raises execution and policy risk until coding/reimbursement pathways normalize. Read More.
• Negative Sentiment: Market reaction and coverage: Media and market reports noted the sharp intraday pullback after guidance — highlights how the guidance reset dominated the beat and forced rapid re-pricing. Read More.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.